Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL PLUS versus PSEUDO 12.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL PLUS versus PSEUDO 12.
DRIXORAL PLUS vs PSEUDO-12
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRIXORAL PLUS contains dexbrompheniramine, an antihistamine that competes with histamine for H1-receptor sites, suppressing histamine-induced symptoms; and pseudoephedrine, a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.
1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.
None Documented
None Documented
Pseudoephedrine: ~9-16 hours (pH-dependent, longer in alkaline urine). Dexbrompheniramine: ~20-25 hours. Clinical context: multiple dosing accumulates.
Terminal elimination half-life: 4-6 hours (adults); 6-8 hours (children); prolonged in renal impairment (up to 20 hours in severe disease).
Renal: 50-70% unchanged for pseudoephedrine; hepatic metabolism for dexbrompheniramine with renal excretion of metabolites.
Renal: 70-90% as unchanged drug; biliary/fecal: <10%
Category C
Category C
Antihistamine/Decongestant
Decongestant